Investigating the role of SARS-CoV-2 and MERS-CoV transcription regulatory sequence (TRS) in viral gene expression and virulence

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 494272

Grant search

Key facts

  • Disease

    COVID-19, Middle East respiratory syndrome coronavirus (MERS)
  • start year

    2023
  • Known Financial Commitments (USD)

    $73,558.84
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Banerjee Arinjay
  • Research Location

    Canada
  • Lead Research Institution

    University of Saskatchewan
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Betacoronavirus (beta-CoV) is one of four genera of coronaviruses (CoVs) that includes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV evolved in 2012 and continues to cause seasonal outbreaks in the Kingdom of Saudi Arabia (KSA), along with travel-related cases. MERS-CoV is listed by the World Health Organization (WHO) as a pandemic threat. SARS-CoV-2 emerged in December 2019 and has caused a global pandemic. MERS-CoV has a higher case fatality rate of approximately 35%, compared to a predicted 2.3% for SARS-CoV-2. Despite epidemiological data suggesting a higher death rate for MERS-CoV infections compared to SARS-CoV-2, little is known about why MERS-CoV is more lethal. CoV gene expression is mediated via viral promoters called transcription regulatory sequence (TRS). All CoV TRSs include a conserved 6-8 nucleotides core sequence (CS) plus variable 5-prime and 3-prime flanking sequences that drive viral gene expression, including expression of viral genes that inhibit antiviral innate and intrinsic host responses. We hypothesize that MERS-CoV and SARS-CoV-2 TRS differentially regulate viral gene expression, which in turn leads to differential inhibition of the type I IFN response by viral proteins. During this five-year study, we will identify differences in molecular markers of disease on infection with MERS-CoV and SARS-CoV-2. We will specifically focus on MERS-CoV and SARS-CoV-2 TRS and identify regions within these sequences that are directly responsible for differential inhibition of protective interferon (IFN) responses. Our study will establish a framework to study accessory proteins, immune response modulation, and viral TRS in CoVs that remain poorly characterized, such as SARS-CoV, porcine epidemic diarrhea virus (PEDV), swine acute diarrhea syndrome coronavirus (SADS-CoV), and pre-emergent bat borne CoVs (BANAL-236, PDF-2180, and others).